different types of glp-1 drugs Drug Comparison in Diabetes and Obesity Treatment Lesson: Oral Semaglutide: A New
Description
The once-daily pill uses drug delivery technology the company acquired in 2020
The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).
Summary Retatrutide, a triple agonist now in phase 3 trials, has the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors.
A lower, fixed dose for those who want a gentle, mindful, cosmetic approach rather than full dose weight loss
GLP-1 receptor agonists, which mimic the hormone Glucagon-Like Peptide-1, are transforming treatment for diabetes and obesity
